 |
 |
|
|
 |
|
Acorda Therapeutics, Inc.
Acorda
Therapeutics, Inc. develops therapeutic products for spinal cord injury
("SCI") and other central nervous system disorders such
as multiple sclerosis (MS). Acorda is focusing its initial development
efforts on a range of therapeutics for individuals with chronic, or
long term, SCI. Currently, there is no therapy that improves neurological
function in chronic SCI patients.
Co-Investors: MDS, MPM, Easton Hunt
|
|
All Investments
Active
Investments
Exited
Investments |
 |
|
Cara Vita
Cara
Vita has developed a cost-effective, health maintenance approach to
caring for the chronically frail elderly in non skilled settings.
While principally a residential care provider, Cara Vita has integrated
private home health and day care programs into its facilities to provide
an alternative for those seniors and their families who are not yet
prepared for a residential program. Cara Vita is built on a care model
designed to enhance resident health and allow high acuity residents
to remain in Cara Vita's facilities longer and age in place gracefully.
Co-Investors: Delphi, Live Oak, Cordova
|
|
|
 |
|
Corus Pharma
Corus
Pharma, a Seattle-based specialty pharmaceutical development company,
is committed to developing and obtaining regulatory approvals of products
for respiratory and infectious diseases that can help provide improved
health and superior quality of life.
Co-Investors: MDS, Novo, JP Morgan
|
|
|
 |
|
Guava Technologies, Inc.
Guava Technologies,
Inc. is a privately-held biotechnology company located in Hayward,
California that develops, manufactures and markets unique, high-impact
cellular analysis systems for the life science research marketplace.
Guava's patented technology has revolutionized the way scientists
perform cell-based analysis.
Co-Investors: HLM, MDS, ProQuest, Abingworth , St. Paul
|
|
|
 |
|
HealthHelp
HealthHelp is a highly successful national radiology quality assurance
program manager that has created significant savings and return
on investment for payers, by decreasing the cost of diagnostic imaging
while increasing the quality of care enrollees receive. HealthHelp
has become the leader in radiology benefit management by providing
innovative, evidence-based programs that provide physicians with
the evidence-based clinical information and support they need when
ordering radiology exams, help managed care organizations identify
radiology and anesthesiology claims paid in error and adopt new
payment policies, educate plan enrollees and their physicians about
the effects of radiation by providing them with the tools to make
informed decisions, assist enrollees in selecting the most cost-effective,
most convenient, and highest quality imaging centers; and ensure
quality imaging through facility and physician evaluations that
use nationally accepted standards.
Co-investors: Essex Woodlands, Sarofim Adler affiliates,
Ed Mashek, Management
|
|
|
 |
|
Napo Pharmaceuticals (LSE: NAPL)
Napo Pharmaceuticals, Inc. is focused on developing and commercializing proprietary pharmaceuticals for the global marketplace, in collaboration with local partners, in order to address major global unmet medical needs in developed and developing countries. Napo is currently developing crofelemer, which is in various stages of clinical development for four distinct product indications, including one product in Phase III, two in Phase II and one in Phase I clinical trials.
Co-Investor: Vulcan
|
|
|
 |
|
National Healing
National
Healing is a disease management company with a focused expertise in
managing wound treatment centers inside client hospitals. The Company
has established 50 clinics with hospital clients including: Columbia,
Quorum, MedCath, and several independent hospitals. In their centers,
National Healing provides high-quality, cost-effective methodologies
to expedite the healing of wounds and reduce inpatient stays.
Co-Investors: Sole Institutional Investor
|
|
|
 |
|
Raven Biotechnologies
Raven Biotechnologies,
Inc. is a privately held company that develops monoclonal (MAb)-based
therapeutics, discovery tools, and technologies using unique, tissue-specific
stem (i.e. progenitor) cells as inputs. While the company's therapeutic
and drug-target discovery platform is applicable to many diseases,
Raven is currently focused on MAb therapies for cancer.
Co-Investors: Bear Stearns Health Innoventures, Biogen Idec New Ventures,
USVP, CMEA, Vulcan, H&Q
|
|
|
|
|
|
|
|
|
|
